Stay updated with breaking news from Early Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- SIFI, a leading international ophthalmic company headquartered in Italy, today announced that it has partnered with Avanzanite Bioscience...
SIFI Announces License Agreement With Avanzanite Bioscience for Akantior® - read this article along with other careers information, tips and advice on BioSpace
- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive ("NRG1+") cancer have been treated with zenocutuzumab ("Zeno") monotherapy - Petosemtamab clinical update planned for first
- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy -...
Live video webcast on Wednesday, January 18th at 11:00 AM ET...